Best Diabetes Companies in Massachusetts, United States
The 38 best Diabetes companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Intarcia.
Ranked: Best Diabetes companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Intarcia 🦄 Provider of osmotic pump for subcutaneous drug delivery | $1.9B | 79 mo ago | 2 | — | — | — |
| 2 | Kailera Developer of therapies for treating obesity and related conditions 60Funding top 12%Growth top 20%News top 22%Moat top 31% All 8 signals ▾Fundingtop 12% Growthtop 20% Newstop 22% Moattop 31% Techtop 40% Talentbottom 41% Globalbottom 38% Marketbottom 36% Funding: Raised $400M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $400M | 10 mo ago | — | Ron Renaud Founder & CEO | — | 1 internship |
| 3 | Fractyl Provider of Endoscopic procedure for type - 2 diabetes | $345M | 62 mo ago | 79 79 → 106 (+34%) | Jay Caplan Co-founder and President | — | — |
| 4 | Beta Bionics Innovating diabetes management with automated bionic pancreas technology | $283M | 21 mo ago | 92 | — | 208 patents Wearable bihormonal patch infusion pumps with smart dosing algorithms and flexible drive mechanisms | — |
| 5 | Semma Therapeutics Provider of bio-artificial pancreas for Type 1 Diabetes treatment | $158M | 90 mo ago | 58 | — | — | — |
| 6 | Cellino Developer of autologous cell therapies | $125M | 23 mo ago | 43 43 → 107 (+149%) | Matthias Wagner Co-Founder & CTO | — | — |
| 7 | Insulet Manufacturer of wearable, tubeless insulin delivery systems for diabetes management | $120M | 147 mo ago | 2,600 2,600 → 5,295 (+104%) | Duane DeSisto Ex-CEO | 1,347 patents Wearable automated insulin pump systems for continuous glucose‑controlled drug delivery. | — |
| 8 | TheracosBio Developer of therapeutics for the treatment of diabetes | $118M | 127 mo ago | 3 | — | 17 patents Advanced pharmaceutical formulation technologies for antimicrobial drug delivery | — |
| 9 | Podimetrics Provider of diabetic foot ulcer monitoring device for patients and doctors | $75M | 45 mo ago | 10 | David Linders Co-founder and CTO | 73 patents Remote monitoring of diabetic foot ulcers, neuropathy, and heart failure via wearable sensors | — |
| 10 | Elevian Developer of regenerative therapies for treating age-related diseases | $61M | 59 mo ago | 6 | Mark Allen Co-Founder & CEO | 7 patents Neuroprotective peptide therapeutics for acute ischemic stroke treatment | — |
| 11 | OcuTerra Therapeutics Developer of eye drop to treat diabetic eye disease | $40M | 32 mo ago | 4 | — | — | — |
| 12 | Regenacy Developer of therapies for treating diabetic and other peripheral nephropathy | $30M | 77 mo ago | 5 | Simon Jones President and CEO | — | — |
| 13 | Mellitus In vitro diagnostic test for Gestational Diabetes Mellitus (GDM) | $16M | 88 mo ago | 10 | — | 11 patents Therapeutic anti‑CD59 antibodies and diagnostic reagents for diabetes biomarkers | — |
| 14 | Akston Biosciences Developer of therapeutics for use in autoimmune Type 1 diabetes prevention, ultra-long-acting insulin… | $14M | 52 mo ago | 61 | — | 165 patents Therapeutic Fc‑fusion biologics for metabolic, oncology and immunotherapy applications | — |
| 15 | AltrixBio Developer of therapeutic solutions for treating diabetes & gastrointestinal diseases | $13M | 11 mo ago | 5 | — | 2 patents Mucoadhesive drug delivery formulations for targeted mucosal administration | — |
| 16 | Common Sensing Digital assets, templates, and creative tools for designers and creators | $10M | 70 mo ago | 17 | — | 41 patents Radiation dose monitoring and liquid measurement systems with integrated temperature sensing | — |
| 17 | Grove Instruments Developer of a non-invasive glucose monitoring device | $9M | 147 mo ago | — | Arthur Combs CEO | — | — |
| 18 | Remedium Bio Developer of gene therapies for a broad range of diseases 7Funding top 37%Moat top 48%Global bottom 36%Tech bottom 22% All 5 signals ▾Fundingtop 37% Moattop 48% Globalbottom 36% Techbottom 22% Marketbottom 20% Funding: Raised $5.6M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 7/100 | $6M | 4 mo ago | 5 | — | — | — |
| 19 | Newton Photonics Develops non-invasive glucometer | $2M | 158 mo ago | — | Paul Melman Co-Founder & CTO | — | — |
| 20 | Fairbanks Pharmaceuticals Togel: Hongkong lottery results, data, and live draw services | $2M | 124 mo ago | — | Alan Schneyer Co-Founder & CEO | — | — |
| 21 | Tolerx Monoclonal antibody for the treatment of autoimmune type 1 diabetes | $2M | 189 mo ago | 13 | — | 55 patents Immunomodulatory biologics targeting GITR, ILT3, and ILT5 for tolerance and cancer therapy | — |
| 22 | Nivarta Early stage drug development company for diabetes and obesity | $1M | 167 mo ago | — | Murali Vemula Founder | — | — |
| 23 | Porosome Developer of therapeutics for secretory and hydration disorders | $1M | 36 mo ago | — | Octavian Bucur Co-Founder | — | — |
| 24 | MelliCell Developer of regenerative therapy for diabetes mellitus | $571K | 28 mo ago | 8 | — | 6 patents Targeted therapeutics and cell-based platforms for obesity and adipocyte-related diseases | — |
| 25 | Apofore Protein therapeutics for diabetes. | $500K | 181 mo ago | — | Patrick Tso Founder | — | — |
| 26 | Energesis Pharmaceuticals Developer of drugs to treat obesity, diabetes, and related metabolic diseases | $419K | 135 mo ago | — | Brian Freeman President & CEO | — | — |
Top 12 Diabetes companies in Massachusetts
#1
Public · Waltham, Massachusetts · founded 2024$400Mraised▾
Developer of therapies for treating obesity and related conditions. It offers a pipeline of drug candidates which include KAI-9531 a GLP-1/GIP receptor dual agonist formulated as an injectable peptide, KAI-7535 is an oral small molecule, KAI-9531 is a GLP-1/GIP receptor, and KAI-9531 is a GLP-1/GIP receptor for the treatment of obesity and type 2 diabetes.
- Oct 2025Series B$600M
- Oct 2024Series A$400M
#2
Series A · Needham, Massachusetts · founded 2020 · 5 employees$5.6Mraised▾
Developer of gene therapies for a broad range of diseases. The company is developing a pipeline of a broad range of therapies for immune and age-related conditions which includes RMD 1101 for rheumatology, RMD 1202 for endocrinology, RMD 1501 for neurology, and RMD 1201 for Type-1 diabetes.
- May 2026Series A$1.5M
- Sep 2024Seed—
- Aug 2023Grant (prize money)$275K
- Aug 2022Seed$2.3M
#3
Public · Boston, Massachusetts · founded 2015 · 92 employees$282.9Mraised▾
Innovating diabetes management with automated bionic pancreas technology. The company pioneers the development of the iLet Bionic Pancreas, an insulin delivery system designed to simplify diabetes management. This innovative technology reduces the burden of decision-making for individuals with diabetes by automating insulin dosing based on continuous glucose monitoring data. The system learns individual insulin needs, eliminating the need for manual carb counting and corrections. The company is dedicated to improving the lives of people with diabetes through user-friendly technological solutions. They focus on creating a supportive community and providing resources for both patients and healthcare professionals. Their commitment extends to ongoing research, clinical trials, and continuous product development to enhance the effectiveness and accessibility of their bionic pancreas system. The company is focused on social impact by making diabetes management easier.
- Nov 2024Series E$60M
- Aug 2023Series D$100M
- Feb 2022Series C$57M
- Sep 2019Grant (prize money)$2M
#4
Series A · Cambridge, Massachusetts · founded 2019 · 5 employees$12.8Mraised▾
Developer of therapeutic solutions for treating diabetes & gastrointestinal diseases. The company has developed drug candidate LuCI that helps in the treatment of gastrointestinal (GI) tract infections and also modulates nutrient contact with the bowel mucosa. It has developed drugs that help in treating diabetes and also reduces fats and glucose levels of the body.
- Sep 2025Series A$5M
- Apr 2025Series A$1.2M
- Mar 2019Series A$6.6M
#5
Series A · Cambridge, Massachusetts · founded 2017 · 43 employees$125Mraised▾
Developer of autologous cell therapies. The company has developed an AI-guided laser editing platform, single-cell laser processing, and robotics to generate autologous induced pluripotent stem cells for regenerative medicines for diseases like Parkinson’s, diabetes, and heart disease.
- Sep 2024Series A$25M
- Jan 2022Series A$80M
- Feb 2021Seed$16M
- Aug 2019Seed$2.5M
#6
Intarcia 🦄Series J · Boston, Massachusetts · founded 1995 · 2 employees$1.9Braised▾
Intarcia Therapeutics offers a drug delivery platform technology. The product is a subcutaneous osmotic mini-pump containing the necessary volume of the drug. Once implanted under the skin, water from the extracellular fluid enters the device and osmotic pressure drives a piston which delivers the drug.
- Jan 2020Series J$198.5M
- Jan 2018Series J$8M
- Aug 2017Series J$524.6M
- Jan 2017Grant (prize money)$90M
#7
Public · Lexington, Massachusetts · founded 2010 · 79 employees$345.3Mraised▾
Provider of Endoscopic procedure for type - 2 diabetes. Fractyl is developing an investigational, device-based, minimally invasive, trans-oral procedure known as Revita duodenal mucosal resurfacing (DMR) that aims to improve the body's response to sugar. Performed using Fractyl’s proprietary Revita System, the DMR procedure uses hydrothermal ablation to modify the lining of the duodenum. Fractyl’s proprietary Revita™ System consists of a console and a novel single-use balloon catheter. The physician first introduces the Revita™ catheter through the mouth into the small intestine using a standard endoscope to visualize the catheter position. The physician then uses the Revita™ System to activate a precisely controlled heated balloon at the end of the catheter to treat the lining of the duodenum. The lining of the duodenum contains cells that affect glucose control and insulin resistance.
- Jun 2021Series F$100M
- Aug 2020Series E$55M
- Mar 2020Series D$44.8M
- Nov 2017Series D$44M
#8
Deadpooled · Boston, Massachusetts · founded 2020 · 4 employees$40.2Mraised▾
Developer of eye drop to treat diabetic eye disease. The lead drug OTT166 is a topical integrin inhibitor used for the treatment of diabetic macular edema and neovascular age-related macular degeneration.
- Dec 2023Series B$25.6M
- Apr 2021Series B$14.6M
#9
Series C · Somerville, Massachusetts · founded 2011 · 10 employees$75.3Mraised▾
Provider of diabetic foot ulcer monitoring device for patients and doctors. It offers a home-monitoring smart mat with sensors that track the blood flow patterns when the patient steps on it and send that data to the cloud to be stored where the data is analyzed and alerts the early signs of foot ulcers. It also responds to reduce inflammation and complications related to foot ulcers.
- Nov 2022Conventional Debt$25M
- Mar 2022Series C$45M
- Aug 2020Series B$8.6M
- Dec 2019Series B—
#10
Acquired · Cambridge, Massachusetts · founded 2015 · 58 employees$158Mraised▾
Semma Therapeutics engages in developing a cell therapy for Type 1 diabetes. It focuses on developing a cell therapy for patients who depend on insulin injections. It discovers a method to generate billions of functional, insulin-producing beta cells in the laboratory. These cells develop in islet-like clusters grown from stem cells. Initial preclinical work in animal models of diabetes has shown that transplantation of these cells is sufficient to control blood glucose levels and the company is currently planning to file an IND for this program. This breakthrough technology has been exclusively licensed (from Melton's lab) to Semma Therapeutics for the development of cell-based therapy for diabetes.
- Feb 2019Series B$114M
- Mar 2017Series A—
- Mar 2016Series A$44M
#11
Series A · Boston, Massachusetts · founded 2017 · 6 employees$60.8Mraised▾
Developer of regenerative therapies for treating age-related diseases. They are developing drugs to increase the activity levels of GDF11 (myostatin(GDF8)-homologous protein) to prevent and treat age-related diseases. They are focused on therapeutic areas including coronary artery disease, Alzheimer's disease, type 2 diabetes, and sarcopenia.
- Sep 2021Series A$40M
- Jul 2020Series A$15.3M
- Sep 2018Seed$5.5M
#12
Public · Boston, Massachusetts · founded 2000 · 2600 employees$120.4Mraised▾
Manufacturer of wearable, tubeless insulin delivery systems for diabetes management. The company develops and provides simple, connected devices for continuous insulin delivery. These devices offer an alternative to multiple daily injections. The company focuses on research and development to improve its technologies.
- Jun 2014Post IPO$201M
- Mar 2009Venture Debt$60M
- Jan 2007Series E$900K
- Feb 2006Series E$50M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diabetes coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.